41,908 Shares in The Chemours Company $CC Purchased by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. bought a new position in The Chemours Company (NYSE:CC) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 41,908 shares of the specialty chemicals company’s stock, valued at approximately $860,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Atlas Capital Advisors Inc. acquired a new stake in shares of Chemours during the 4th quarter worth approximately $26,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Chemours in the 4th quarter worth approximately $28,000. Covestor Ltd lifted its holdings in shares of Chemours by 204.7% in the 4th quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company’s stock worth $31,000 after purchasing an additional 1,748 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in Chemours during the 4th quarter valued at approximately $31,000. Finally, Rothschild Investment LLC boosted its position in Chemours by 87.0% during the 4th quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company’s stock valued at $32,000 after purchasing an additional 1,255 shares during the period. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on CC. Royal Bank Of Canada dropped their target price on Chemours from $26.00 to $22.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Morgan Stanley set a $18.00 price target on shares of Chemours in a report on Monday, August 10th. Truist Financial lowered their price target on shares of Chemours from $30.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $17.00 price objective on shares of Chemours in a report on Thursday, August 13th. Finally, Zacks Research downgraded shares of Chemours from a “strong-buy” rating to a “strong sell” rating in a research report on Tuesday, August 11th. Five equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $20.10.

Insiders Place Their Bets

In other Chemours news, insider Calderon Gerardo Familiar purchased 1,935 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were purchased at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the transaction, the insider owned 58,547 shares in the company, valued at $909,234.91. The trade was a 3.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Denise Dignam purchased 3,378 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was acquired at an average cost of $14.95 per share, with a total value of $50,501.10. Following the completion of the acquisition, the chief executive officer directly owned 339,916 shares in the company, valued at $5,081,744.20. The trade was a 1.00% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 8,663 shares of company stock worth $130,601 over the last ninety days. Company insiders own 0.85% of the company’s stock.

Key Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $2.05 from $1.95 and increased Q4 2027 EPS to $0.61 from $0.53, suggesting improved profitability may emerge beyond 2026.
• Positive Sentiment: The firm also lifted estimates for Q1 2027 EPS to $0.40 from $0.39, Q3 2027 EPS to $0.58 from $0.56, Q1 2028 EPS to $0.56 from $0.55, and Q2 2028 EPS to $0.65 from $0.61.
• Neutral Sentiment: The revisions indicate a potentially stronger longer-term earnings trajectory, but they are offset by weaker expectations for the company’s immediate results. Zacks’ current full-year EPS consensus is approximately $0.87.
• Negative Sentiment: Zacks cut its FY2026 EPS forecast to $0.83 from $0.90 and reduced Q4 2026 EPS to $0.11 from $0.12, signaling pressure on near-term earnings.
• Negative Sentiment: The largest revision was a reduction in Q3 2026 EPS to $0.25 from $0.41. That forecast implies a substantial decline from the previous estimate and could weigh on investor sentiment.
• Negative Sentiment: FY2028 EPS was also lowered to $2.31 from $2.38, indicating that longer-term optimism is not broad-based. Chemours recently missed quarterly revenue and EPS expectations, adding to concerns about operating momentum.

Chemours Trading Down 0.1%

NYSE:CC opened at $15.96 on Monday. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of -8.36 and a beta of 1.43. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. The Chemours Company has a 1 year low of $10.44 and a 1 year high of $28.67. The business has a fifty day moving average of $18.01 and a 200-day moving average of $20.05.

Chemours (NYSE:CC) last issued its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.07). The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.65 billion. Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. Chemours’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.54) earnings per share. Equities analysts predict that The Chemours Company will post 0.87 earnings per share for the current year.

Chemours Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 14th will be issued a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.35 annualized dividend and a yield of 2.2%. Chemours’s payout ratio is presently -18.32%.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.